← Leaderboards
Jennifer June Sessions
Cynvec, Llc
$1,200,000
Attributed
$2,400,000
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2020–22$2M$1.5M$1M$500K$0
'20
'21
'22
Funding mix
By agency
NIH$2,400,000 · 1
By mechanism
R44$2,400,000 · 1
Top collaborators
- Daniel Meruelo3 shared
Others in their field
Other Emerging Leaders on “Disease Remission”
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$72,037,072
- Julie Ake · National Institute Of Allergy And Infectious Diseases$40,742,120
- Christopher Barnaby Nelson · University Of Melbourne$28,817,917
- Rene S. Kahn · Icahn School Of Medicine At Mount Sinai$13,240,338
- Magdalena Elzbieta Sobieszczyk · Columbia University Health Sciences$12,286,513
- Deanna A Kulpa · Emory University$8,444,989
Research focus
Disease RemissionAnimal ModelAntibodiesAutomobile DrivingBaseAntigen PresentationAntitumor ResponseCancer ImmunotherapyCancer Testis AntigenCancer TherapyCause Of DeathCellsBiotechnologyChemotherapyClinical ProtocolsCancer CellCombination ImmunotherapyCommercializationComparative EfficacyCostCtag1 GeneCurative TreatmentsDesignDisseminated Malignant Neoplasm
Grant awards (3)
A novel and effective immunotherapeutic approach for tumors with a low mutational load and few tumor-infiltrating lymphocytes, such as ovarian cancer$866,737
R44 · FY2022 · CA · contact PI
A novel and effective immunotherapeutic approach for tumors with a low mutational load and few tumor-infiltrating lymphocytes, such as ovarian cancer$1,133,263
R44 · FY2021 · CA · contact PI
A novel and effective immunotherapeutic approach for tumors with a low mutational load and few tumor-infiltrating lymphocytes, such as ovarian cancer$400,000
R44 · FY2020 · CA · contact PI